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Two histologically colorectal carcinomas
subsets from the serrated pathway show
different methylome signatures and
diagnostic biomarkers
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Abstract
Background: Altered methylation patterns are driving forces in colorectal carcinogenesis. The serrated adenocarcinoma
(SAC) and sporadic colorectal carcinoma showing histological and molecular features of microsatellite instability (hmMSI-
H) are two endpoints of the so-called serrated pathological route sharing some characteristics but displaying a totally
different immune response and clinical outcome. However, there are no studies comparing the methylome of these two
subtypes of colorectal carcinomas. The methylation status of 450,000 CpG sites using the Infinium Human Methylation
450 BeadChip array was investigated in 48 colorectal specimens, including 39 SACs and 9 matched hmMSI-H.
Results: Microarray data comparing SAC and hmMSI-H showed an enrichment in functions related to morphogenesis,
neurogenesis, cytoskeleton, metabolism, vesicle transport and immune response and also significant differential
methylation of 1540 genes, including CD14 and HLA-DOA which were more methylated in hmMSI-H than in SAC
and subsequently validated at the CpG, mRNA and protein level using pyrosequencing, quantitative polymerase
chain reaction (qPCR) and immunohistochemistry.
Conclusions: These results demonstrate particular epigenetic regulation patterns in SAC which may help to
define key molecules responsible for the characteristic weak immune response of SAC and identify potential
targets for treating SAC, which lacks molecular targeted therapy.
Keywords: Colorectal cancer, Methylome, Serrated, Immune response, Microsatellite instability, Epigenetics, Colon
carcinogenesis, CD14, HLA-DOA
Background
Serrated polyp pathway is considered as an alternative
pathological sequence to the so-called adenoma-carcinoma
sequence which is typically characterized by chromosomal
instability and by ending up in the development of conven-
tional carcinoma (CC) [1]. Less is known about the CRCs
developed mainly in proximal colon through the serrated
pathway, although high-level of microsatellite instability
(MSI-H), BRAF mutation and CpG island methylation
phenotype (CIMP) seems to be the driven forces in this car-
cinogenic process. The CRC showing histological and mo-
lecular features of MSI-H (hmMSI-H) [2, 3] is considered
as one endpoint of the serrated route as well as serrated
adenocarcinoma (SAC) which has a typical serrated morph-
ology and remnants of serrated polyps (SP) adjacent to the
invasive tumour [4, 5]. SAC has been recognized in the lat-
est WHO classification of tumours of the digestive system
as a new subtype of colorectal cancer (CRC) [6], accounting
for 7.5 to 8.7% of all CRCs [5, 7] approximately one third of
serrated pathway CRCs [8] and most are microsatellite
stable (MSS) and can be either BRAF or KRAS mutated
[9–11]. Criteria for SAC histologic diagnosis have been
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proposed [7] and recently validated in a series of 85 cases,
and it has been shown to have a worse prognosis than con-
ventional carcinoma (CC) [5]. Accordingly, SAC displays a
higher frequency of adverse histological features at the inva-
sive front including high-grade tumour budding and cyto-
plasmic pseudofragments, infiltrating growth pattern and
weak peritumoural lymphocyte response [12]. Besides,
mRNA microarray studies have demonstrated that SAC
has a different expression profile compared to CC [13, 14].
Despite these features, there are no studies assessing the
differences in the molecular signatures of SAC and the typ-
ical hmMSI-H nor specific markers nor the clinical differ-
ences between these two CRC subtypes.
Based on an initial histological evaluation, we aimed in
this work to investigate the following issues:
-To discern which are the differentially methylated
functions between SAC and hmMSI-H and if these
could explain the histologic characteristics of these two
entities
-To identify and validate at different levels those differ-
entially methylated genes so they could be used as diag-
nostic markers or potential therapeutic targets
Results
The clinico-pathological features of the patients have been
previously reported [5, 10] and are shown in Table 1.
SACs were diagnosed on the basis of criteria proposed by
Mäkinen et al. [7] and hmMSI-H according to prior estab-
lished criteria [2] (Fig. 1). No significant differences were
observed for confounding variables between SAC and
hmMSI-H in the training and validation series (Table 1).
Differentially methylated functions
Bioinformatic analysis revealed a considerable number
of GO biological processes (BP) differentially methylated
in SAC vs. hmMSI-H: 40 GO terms obtained using Clus-
terProfiler while 76 terms where found using FatiGo
(Additional file 1: Table S1). In general, differentially
methylated genes were enriched for GO-BP terms re-
lated with biosynthesis (GO:0034654, GO:0031326,
GO:0044271, GO:0018130); nitrogen and nucleic acid
metabolism (GO:0090304, GO:0060255, GO:0051173,
GO:0006807); RNA activity and transcription regulation
(GO:0006355, GO:0032774, GO:2001141); protein secre-
tion (GO:0051051, GO:0051047), neurogenesis (GO:005
1960, GO:0030182, GO:0022008, GO:0030900), morpho-
genesis (GO:0048598, GO:0048562, GO:0009887, GO:00
16331), sensory perception (GO:0007608, GO:0050911,
GO:0050906); cytoskeleton and cell movement (GO:00
48870, GO:0016477, GO:0051674) and immune re-
sponse (GO:0002250).
The scatterplot obtained using REVIGO shows the GO
biological processes which are differentially methylated
between SAC and hmMSI-H after the redundancy reduc-
tion (Fig. 2). GO cellular component and molecular func-
tion categories are shown as Additional file 2: Figure S1.
Differentially methylated genes
The analysis of the methylome microarray data identified
1540 differentially methylated genes, 266 of which were
more methylated in SAC than in hmMSI-H (Add-
itional file 3: Table S2). No significant methylated genes
were observed when comparing normal mucosa from
SAC and normal hmMSI-H mucosa or when comparing
Spanish and Finnish serrated tumour cases. Table 2 shows
the list of the 42 most differentially methylated genes as
obtained from the array analysis. Functions associated
with these genes are shown in Additional file 4. Based on
the extent of differential methylation grade, the import-
ance of the biological functions, the design of suitable
primers and the availability of antibodies, we decided to
validate HLADOA and CD14 at the DNA, mRNA and
protein level. CD14 is a surface antigen, preferentially
expressed on monocytes/macrophages that cooperate with
other proteins to mediate the innate immune response to
bacterial lipopolysaccharide. Alternative splicing results in
multiple transcript variants (NCBI RefSeqs NM_000591.3,
NM_001040021.2, NM_001174104.1, NM_001174105.1)
encoding the same protein. HLA-DOA, in turn, is a mem-
ber of the HLA class II which forms a heterodimer with
HLA-DOB. This heterodimer, HLA-DO, is found in lyso-
somes in B cells and regulates HLA-DM-mediated peptide
loading on MHC class II molecules.
Validation of methylated sites by pyrosequencing
The distribution of CpG islands in HLA-DOA and CD14
enabled the design of primers to quantify the level of
CpG methylation in these genes by pyrosequencing
upon bisulfite-treated DNA. As shown in Table 3, the
methylation percentage in CD14 was generally lower
than that in HLA-DOA CpG sites. Intriguingly, tumoural
specimens from SAC, but not hmMSI-H cases, showed
lower methylation level of HLA-DOA than normal adja-
cent samples. In contrast, CpG2 site from CD14 dis-
played higher methylation in tumoural than in normal
specimens from hmMSI-H patients, whereas no such
significant difference was observed in SAC cases. Con-
sistent with the microarray results, the percentage of
CpG methylation in HLA-DOA and CD14 was higher in
hmMSI-H than in SAC at all CpG sites studied except
for CpG3 in HLA-DOA (Table 3).
Validation by qPCR
With the aim of finding out whether higher CpG methy-
lation in HLA-DOA and CD14 in hmMSI-H correlates
with a decreased expression of these genes, an analysis
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of the expression of HLA-DOA and CD14 mRNA by
quantitative PCR was performed. HLA-DOA expression
did not show differences between tumoural and normal
mucosa (median 0.00438 vs. 0.00467; p = 0.531), whereas
CD14 expression was lower in tumoural than in normal
mucosa, although not reaching statistical significance
(median 0.0128 vs. 0.0599; p = 0.098). There were no
differences when comparing tumoural and normal mu-
cosa for each CRC subtype (Table 4). The qPCR results
validated the microarray and pyrosequencing results as
CRC cases with serrated histology showed higher ex-
pression of CD14 (median 0.133 vs. 0.004; p = 0.004) and
HLA-DOA (median 0.099 vs. 0.006; p = 0.047) than
hmMSI-H cases, respectively (Fig. 3/Table 4).
Fig. 2 Terms of Gene Ontology biological processes enriched in the comparison between SAC and hmMSI-H for their methyloma profile. The
scatterplot shows the biological processes which are globally differentially methylated between SAC and hmMSI-H after GO term redundancy
reduction. The graph is represented in a two-dimensional space derived by applying multidimensional scaling to a matrix of the GO terms’
semantic similarities [35]. Terms associated with higher methylation in hmMSI-H are shown in red squares. Colour intensity indicates level of
significance (log10 p value). Circle diameter indicates number of genes for each biological process
Fig. 1 Histological morphology of colorectal cancer subtypes (H-E staining). a Serrated adenocarcinoma (SAC) showing serrated glands with
large, rounded nuclei with prominent nucleoli and ample eosinophilic cytoplasm. Original magnification × 20. b Colorectal carcinoma showing
histological and molecular features of microsatellite instability (hmMSI-H). The image represents a microglandular monomorphic pattern with a
small area of necrosis. Original magnification × 15
García-Solano et al. Clinical Epigenetics          (2018) 10:141 Page 4 of 12
Table 2 List of the 42 most differentially methylated genes (37 more methylated in hmMSI-H and 5 in SAC) as obtained from the
array analysis
Gene symbol >methyl. in adj p val. Gene name Chr
PDCD2L hmMSI-H 0.00101 Programmed cell death 2-like 19
FGFR2 SAC 0.00147 Fibroblast growth factor receptor 2 10
CTSL2 hmMSI-H 0.00159 Cathepsin L2 9
TLR4 hmMSI-H 0.00159 Toll-like receptor 4 9
ANKRD10 hmMSI-H 0.00350 Ankyrin repeat domain 10 13
COPZ1 hmMSI-H 0.00420 Coatomer protein complex, subunit zeta 1 12
C17orf108 SAC 0.00420 Chromosome 17 open reading frame 108 17
CEP68 hmMSI-H 0.00580 Centrosomal protein 68 kDa 2
ZNF652 hmMSI-H 0.00580 Zinc finger protein 652 17
PCYOX1L hmMSI-H 0.00583 Prenylcysteine oxidase 1 like 5
GALNT11 hmMSI-H 0.00583 UDP-NADG:polypeptide N-acetylgalactosaminyltransferase 11 7
MICAL2 hmMSI-H 0.00583 Microtubule-associated monoxygenase, calponin and LIM domain 2 11
OSCP1 hmMSI-H 0.00583 Organic solute carrier partner 1 1
ACAD10 hmMSI-H 0.00583 Acyl-CoA dehydrogenase family, member 10 12
MELK hmMSI-H 0.00583 Maternal embryonic leucine zipper kinase 9
HLA-DOA hmMSI-H 0.00583 Major histocompatibility complex, class II, DO alpha 6
KRT20 hmMSI-H 0.00583 Keratin 20 17
TMEM45B hmMSI-H 0.00583 Transmembrane protein 45B 11
LOC285401 SAC 0.00641 Uncharacterized LOC285401 3
PPIL1 hmMSI-H 0.00650 Peptidylprolyl isomerase (cyclophilin)-like 1 6
CA13 hmMSI-H 0.00709 Carbonic anhydrase XIII 8
BCL7C hmMSI-H 0.00709 B cell CLL/lymphoma 7C 16
CD14 hmMSI-H 0.00850 CD14 molecule 5
PLA2G4C hmMSI-H 0.00905 Phospholipase A2, group IVC (cytosolic, calcium-independent) 19
LY6G6D hmMSI-H 0.00908 Lymphocyte antigen 6 complex, locus G6D 6
TCF7L2 hmMSI-H 0.00954 Transcription factor 7-like 2 (T-cell specific, HMG-box) 10
RP11-165H20.1 hmMSI-H 0.00954 CHIA-like pseudogene 1
CHD6 hmMSI-H 0.00954 Chromodomain helicase DNA-binding protein 6 20
PARN hmMSI-H 0.00954 Poly(A)-specific ribonuclease 16
KCNK15 hmMSI-H 0.00954 Potassium channel, subfamily K, member 15 20
TMEM209 hmMSI-H 0.01015 Transmembrane protein 209 7
GOLM1 hmMSI-H 0.01016 Golgi membrane protein 1 9
ARRDC1 hmMSI-H 0.01016 Arrestin domain containing 1 9
TRIM21 hmMSI-H 0.01016 Tripartite motif containing 21 11
PHAX hmMSI-H 0.01016 Phosphorylated adaptor for RNA export 5
NMT2 hmMSI-H 0.01016 N-myristoyltransferase 2 10
ATP12A hmMSI-H 0.01016 ATPase, H+/K+ transporting, nongastric, alpha polypeptide 13
ARHGAP30 SAC 0.01016 Rho GTPase-activating protein 30 1
WWP1 hmMSI-H 0.01055 WW domain-containing E3 ubiquitin protein ligase 1 8
GNAI3 hmMSI-H 0.01055 Guanine nucleotide binding (G protein), α inhibit polypeptide 3 1
CD48 SAC 0.01055 CD48 molecule 1
EXPH5 hmMSI-H 0.01070 Exophilin 5 11
Genes chosen for validation by pyrosequencing, qPCR, and IHC are written in bold letters
SAC serrated adenocarcinoma, hmMSI-H colorectal carcinoma showing molecular and histological features of microsatellite instability
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Validation by immunohistochemistry
In order to investigate whether differential methylated
status of HLA-DOA and CD14 in SAC compared to
hmMSI-H could have an effect on protein expression
within the tissue cells, immunohistochemistry for both
HLA-DOA and CD14 was performed. Figure 4 shows
the staining pattern for CD14 being cytoplasmic in stro-
mal cells, not only in myeloid cells from monocyte/
macrophague linage but also in some endothelial, (lower
left image) whereas for HLA-DOA mantle zone cells
from a lymph node were positive (lower right image). In
SAC cases, a positive membranous staining for CD14
was observed in some stromal cells and lymphocytes
with no expression in neoplastic glands. As shown in
Fig. 4, the expression of CD14 was also absent in neo-
plastic glands from hmMSI-H cases and only few stro-
mal cells stained positive and no staining was observed
in lymphocytes. In tumoural cases, an intense cytoplas-
mic and luminal secretion staining for HLA-DOA was
observed in SAC neoplastic glands whereas weak cyto-
plasmic expression considered as negative was observed
in hmMSI-H tumour cells. In both cases, stromal cells
were negative (Fig. 4).
Surprisingly, negative or weak expression of CD14 was
statistically more frequent in SAC than in hmMSI-H
(81.8% vs. 42.9%; p = 0.008) (Fig. 4; Table 5). As ex-
pected, moderate/strong HLA-DOA staining was higher
in SAC than in hmMSI-H (30.8% vs 0%; p = 0.005), thus
confirming array, pyrosequencing and qPCR results.
Association of CD14/HLA-DOA methylation with KRAS/
BRAF/MSI-H status
In order to ascertain the relationship between the
methylation of these genes with common biomarkers
used in the clinical management of CRC, we performed
an association study using the cases of DNA validation
set. The results in Table 6 show that CD14 methylation
is significantly associated with wild-type KRAS, V600E
mutant BRAF and microsatellite instability. HLA-DOA
methylation did not correlate with these markers except
for a tendency with microsatellite instability (p = 0.069).
Discussion
A two-arm model has been proposed to explain the pro-
gression of the serrated pathway, the aberrant crypt
foci-hyperplastic type being the earliest lesion which
may develop into hyperplastic polyps and sessile serrated
Table 3 Pyrosequencing for the relative quantitation of CpG methylation in CD14 and HLA-DOA genes
Gene CD14 HLA-DOA
CpG site CpG1 CpG2 CpG1 CpG2 CpG3
SAC-T (n = 16) Mean 6.89 13.56 33.83 34.95 89.78
SD 5.53 8.06 15.47 14.91 8.04
hMSI-H-T (n = 9) Mean 13.64 22.38 50.94 48.12 94.61
SD 6.15 8.9 14.81 13.62 2.36
SAC-T vs. hmMSI-H p value 0.010 0.020 0.013 0.039 0.14
SAC-N (n = 8) Mean 7.97 13.86 60.02 58.27 100
SD 3.19 2.19 2.01 2.94 0
MSI-N (n = 6) Mean 8.25 13.72 53.13 53.26 98.69
SD 2.36 2.37 6.73 8.92 2.75
SAC-T vs. SAC-N p value 0.616 0.911 0.0001 0.0003 0.006
hmMSI-H-T vs. hmMSI-H-N p value 0.064 0.038 0.742 0.432 0.002
SAC-N vs hmMSI-N p value 0.860 0.911 0.017 0.159 0.271
SAC-T tumoural tissue from serrated adenocarcinoma, hmMSI-H-T tumoural tissue from histological and molecular high-level microsatellite unstable colorectal
carcinoma, SAC-N normal tissue adjacent to SAC, hmMSI-H-N normal tissue adjacent to hmMSI-H
Table 4 Quantitative analysis of the CD14 and HLA-DOA mRNA
expression in tumour and adjacent normal mucosa
Gene Sample type N Mean ± SD Median IR
CD14 SAC-T 19 0.166 ± 0.16 0.133 0.509
hmMSI-H-T 22 0.066 ± 0.16 0.004 0.718
p value 0.004
SAC-N 7 0.191 ± 0.17 0.198 0.386
hmMSI-H-N 7 0.129 ± 0.24 0.037 0.667
p value 0.383
HLA-DOA SAC-T 19 0.0617 ± 0.11 0.099 0.375
hmMSI-H-T 22 0.021 ± 0.03 0.006 0.138
p value 0.047
SAC-N 7 0.135 ± 0.01 0.0098 0.034
hmMSI-H-N 7 0.07 ± 0.008 0.037 0.021
p value 0.620
SAC-T tumoural tissue from serrated adenocarcinoma, hmMSI-H-T tumoural
tissue from histological and molecular high-level microsatellite unstable
colorectal carcinoma, SAC-N normal tissue adjacent to SAC, hmMSI-H-N normal
tissue adjacent to hmMSI-H
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adenomas, or into traditional serrated adenomas, both
of which may progress to CRC having serrated histology
such as SAC and to CRC with histological and molecular
features of microsatellite instability (hmMSI-H). Despite
that these two CRC subtypes seem to share a common
pathological route, the clinical manifestation and prog-
nosis is surprisingly different. On the one hand, hmMSI
is associated with an abundant immune response and
good prognosis [15]. On the other hand, SAC has a
worse outcome that conventional CRC as it displays a
high frequency of histological adverse prognostic factors,
the weak immune response being one of them, along
with high tumour budding and infiltrative growth pat-
tern. It is therefore important to study which molecular
features distinguish SAC and hmMSI-H, not only for
understanding the serrated polyp pathway but also for
providing diagnostic markers and molecular targets for
histology-based specific treatments. In this study, which
is the first comparing the methylome of these two en-
tities, we have observed important differences in the
functions associated with methylated genes from each
tumour type. First, most of these genes were more meth-
ylated in hmMSI-H than in SAC, thus suggesting that,
in general, MSI-H development might more associated
with aberrant hypermethylated, and thus silencing, genes
than SAC. Given that differentially methylated genes
were more methylated in SAC than in CC [16], SAC
would show an intermediate hypermethylation status be-
tween hmMSI-H and CC. Functions differentially meth-
ylated are mostly related to metabolism, morphogenesis,
neurogenesis, cytoskeleton and immune response. These
findings are consistent with previous works analysing
the expression profile of SAC highlighting the
over-representation of these biological activities when
compared to CC [13, 14]. Evasion of immune response
has been proposed as an emerging hallmark of cancer,
and in fact, weak peritumoural lymphocytic infiltration
(PLI) is considered as one histological adverse prognos-
tic factor [17, 18]. All this evidence is also consistent
with the higher frequency of tumour infiltrating and
peritumoural lymphocytes and “Crohn-like” inflamma-
tory response found in hmMSI-H and the weak PLI and
worse prognosis which characterize SAC [12]. This find-
ing raises the question of which molecular factors deter-
mine these differences between these two CRCs. One
possible explanation comes from the fact that hmMSI-H
CRC, due to the dysfunction of the DNA mismatch re-
pair machinery, generates a high number of neoantigens
that stimulate the immune system whose effector cells
are attracted to the tumour invasive front [19]. Given
the allegedly common origin of hmMSI-H and SAC and
some molecular similarities, one challenging therapeutic
approach for SAC might be to make this CRC subtype
recognizable for the immune system. In order to know
which steps in the immune response could be affected, a
list of significantly methylated genes has been obtained
in this work most of them belonging to immune
response.
From those significantly methylated genes, CD14 and
HLADOA were chosen to be validated at the DNA,
mRNA and protein level. CD14 is protein involved
expressed mainly by monocyte/macrophage cell al-
though some non-myeloid lineage cells such epithelial
can also express it [20]. Apart from its role in response
Fig. 3 qPCR results of the mRNA expression of CD14 and HLA-DOA genes in SAC and CC tumoural tissue as well as in adjacent non-tumoural
specimens. Asterisk indicates statistical significance.*p > 0.05; ***p > 0.005
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against sepsis, recent reports have found that CD14+ cir-
culating monocytes and CD14+ tumour infiltrating mac-
rophages are more frequently found in patients with
CRC compared to healthy controls, these findings being
associated with a higher plasma concentration of the im-
munosuppressive cytokine, IL10 [21]. These CD14+
monocytes are a subset of myeloid-derived suppressor
cells (MDSC) which are key mediators in the negative
regulation of immune responses [22]. Therefore, the
observed methylation and CD14 gene silencing could
have an immunostimulatory effect in MSI-H CRCs in
contrast to SAC where CD14 gene is less methylated
and, subsequently, more expressed. Despite that our
study validates CD14 microarray result at the DNA and
mRNA level, it was not able to confirm a lower expres-
sion of the CD14 protein in hmMSI-H. Possible reasons
for that finding could be the expression of specific CD14
transcripts by myeloid cells or non-myeloid with other
functions than immune tolerance or the fact that CD14
is also expressed by non-myeloid cells [20], thus making
complicated its histological evaluation. Supporting the
conflicting nature of this issue, some other studies
have reported that CD14+ macrophages at the inva-
sive front correlates with a more favourable prognosis
in CRC patients with metastasis [23]. The expression
of molecules expressed by immune cells such as
CD14 will be dependent on the overall presence of
these cells in the tumour microenvironment. One of
our aims was to characterize molecules or immune
cell types that are responsible for the difference ob-
served between SAC and hmMSI-H. The higher
CD14 methylation and the decreased gene expression
observed in hmMSI-H stress the point that, despite
hmMSI-H having a remarkable immune response,
some kind of difference in the CD14 function may
exist between SAC and hmMSI-H.
Human leukocyte antigen (HLA) family members are
antigen-presenting molecules which are expressed by
virtually all cells in human body, including cancer cells,
although the downregulation or aberrant expression of
these molecules are used by the tumour to avoid im-
mune response [24]. As regards to HLA-DOA, we vali-
dated the higher methylation and lower mRNA and
protein expression in hmMSI-H compared to SAC. Very
little is known about that protein as there are no studies
linking it to colorectal carcinoma. Archer et al., by ana-
lysing the methylation status of 1505 CpG sites in hepa-
tocellular carcinoma (HCC) tissue and comparing it
with paired pre-neoplastic non-tumourous specimens
from the same patients, observed that HLA-DOA was
hypomethylated in tumoural tissue [25]. This finding
Fig. 4 Immunohistochemical expression of CD14 and HLA-DOA in
serrated adenocarcinoma (SAC) and CRC showing histological and
molecular features of microsatellite instability (hmMSI-H) and in
normal tissue (intestinal lamina propria and lymph node, respectively).
Original × 40 magnification in all except in HLA-DOA in hmMSI-H (× 20)
Table 5 Immunohistochemical expression of CD14 and HLA-DOA proteins
Protein Sample type n Distribution (A–C)
Intensity (1–3) score
Two-tier score p value (Fisher)
A1 A3 B2 B3 C3 Negative/weak (A1-B2) Moderate/strong (B3-C3)
CD14 SAC 26 11 10 0 3 2 21 (81.8) 5 (19.2)
hmMSI-H 21 3 6 0 5 7 9 (42.9) 12 (57.1) 0.008
HLA-DOA SAC 26 9 8 1 8 0 18 (69.2) 8 (30.8)
hmMSI-H 21 17 4 0 0 0 21 (100) 0 0.005
Immunohistochemical markers in the tumours were evaluated by considering the distribution area score (A < one third, B = between one and two thirds,
C = two-thirds-whole area) and the staining intensity (1 = none or weak staining, 2 = moderate, 3 = strong)
SAC serrated adenocarcinoma, hmMSI-H-T colorectal carcinoma with histological and molecular high-level microsatellite instability
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supports a role of HLA-DOA, not only in HCC but in
CRC tumour development. In agreement, our results in
CRC also demonstrated a lower methylation in CRC
compared to adjacent normal specimens, regardless the
histological type of CRC. This observation did not reach
statistical significance at the mRNA expression level,
thus suggesting additional factors involved in the regula-
tion of HLA-DOA expression. Very few articles corre-
lated HLA-DOA with immune response features. Wang
et al. reported that hypomethylation of CpGs in 6p21.3,
where HLA-DOA is located, was associated with in-
creased CD8 T cell tumour infiltration in serous ovarian
cancer [26] whereas Ningappa et al. and Sindhi et al.
demonstrated that HLA-DOA inhibits B cell presenta-
tion of antigen and consequently these authors proposed
a potentially novel antirejection drug target [27, 28]. Our
results are in line with these latter works; as transcrip-
tion of major histocompatibility genes is silenced by
DNA methylation [29] of upstream promoters, it would
not be surprising that higher HLA-DOA methylation in
hmMSI-H might have an effect on enhancing antigen
presentation by B cells and generate a more prominent
immune response.
Conclusions
Our study identifies key functions and genes that might
be important for understanding two CRC histological
subtypes sharing a common pathological route but de-
veloping a dissimilar immune response and having a dif-
ferent clinical outcome. However, subsequent studies are
needed to further characterize the interplay between the
immune microenvironment and the tumour CRC cells
in the serrated pathway.
Material and methods
Patients and tumour samples
SACs were diagnosed on the basis of criteria proposed by
Mäkinen et al. (epithelial serrations, clear or eosinophilic
cytoplasm, abundant cytoplasm, vesicular nuclei, absence
of or less than 10% necrosis of the total surface area,
mucin production and cell balls and papillary rods in mu-
cinous areas of a tumour) [7]. hmMSI-H were diagnosed
according to prior established criteria (mucinous,
signet-ring cell, and medullary carcinoma, tumour infil-
trating and peritumoural lymphocytes, “Crohn-like”
inflammatory response, poor differentiation, tumour het-
erogeneity and “pushing” tumour border) (Fig. 1) [2]. Fro-
zen samples of 21 and 18 SACs were retrieved from Santa
Lucia General University Hospital (HGUSL), Cartagena,
Spain, and Oulu University Hospital, Oulu, Finland, re-
spectively. Additionally, nine matched hmMSI-H from
HGUSL were included for the methylome microarray
study. Validation by methylated sequences was performed
on 16 Spanish SAC cases and nine hmMSI-H from the
microarray subset. Validation by qPCR was performed
upon frozen specimens of 12 SAC and nine hmMSI-H,
and in addition, adjacent normal mucosa was also ana-
lysed from eight SACs and six hmMSI-H. Paraffin blocks
of 26 SAC and 21 matched hmMSI-H, included in previ-
ous works, [10, 14] were used for immunohistochemistry
(IHC) validation. The assessment of the MSI-H condition
was confirmed at the molecular level as described previ-
ously by our group [10], and none of the hmMSI-H
showed serrated morphology. The cases from DNA valid-
ation set were used to assess the correlation between gene
methylation and KRAS, BRAF and MSI status. The study
was approved by the Hospital Ethics Committee and was
carried out in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments. Written informed consent was obtained
from all the patients.
DNA extraction
A volume of approximately 10 mm3 was extracted from
each frozen tissue using the disposable sterile biopsy
punch. DNA was extracted following the manufacturer’s
instructions (Qiagen, Hilden, Germany). Briefly, tissue
was disrupted and homogenized in ATL buffer using a
Tissueruptor (Qiagen), incubated with proteinase K and
the homogenate was subjected to automatic DNA ex-
traction using the Qiacube equipment and the QiaAmp
DNA Mini Kit (cat no.:51306), both provided by Qiagen.
Bisulfite treatment and DNA methylation assay
HumanMethylation450K BeadChip (Illumina, Inc., San
Diego, CA), using Infinium HD Methylation assay for
genome-wide DNA methylation screening, was employed.
In brief, genomic DNA (1000 ng) from each sample was
bisulfite converted with the EZ DNA Methylation Kit
(Zymo Research, Orange, CA) according to the manufac-
turer’s recommendations. Bisulfite-treated DNA was iso-
thermally amplified at 37 °C (20–24 h), and the DNA
Table 6 Association of CD14 and HLA-DOA methylation
(measured as percentage of methylated cytosine) with
common colorectal carcinoma biomarkers (KRAS, BRAF, MSI)
Biomarker* CD14 HLA-DOA
Median IR p value Median IR p value
KRAS Mutated 9.20 5.9 35.97 38.8
Wild-type 15.355 12 0.022 40.37 33.7 0.290
BRAF Mutated 16.68 21.7 39.63 35.5
Wild-type 12.845 6.4 0.035 37.53 36.2 0.82
MSI Unstable 16.7 19.1 40.95 30.2
Stable 11.32 6.1 0.001 31.9 39.6 0.069
*Codon 12 and 13 mutations in KRAS and V600E mutation in BRAF were
considered. CpG site 2 for CD14 and CpG site 2 for HLA-DOA were considered.
Similar results were obtained for site 1 (data not shown)
IR interquartile range, MSI microsatellite instability
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product was fragmented by an endpoint enzymatic
process, then precipitated, resuspended, applied to an Infi-
nium Human Methylation450K BeadChip (Illumina, San
Diego, CA, USA), and hybridized at 48 °C (16–24 h). The
fluorescently stained chip was imaged by the Illumina
i-SCAN, and Illumina’s Genome Studio program (Methy-
lation Module) was used to analyse BeadArray data to as-
sign site-specific DNA methylation β-values to each CpG
site. The data set supporting the results of this article are
available in the GEO repository, GSE68060 in https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68060.
Preprocessing of methylation data
Processing of raw data was done using R packages.
Probes with a low detection p value (p < 0.01) in more
than 95% of the samples and those measuring SNPs or
mapping in X or Y chromosomes were removed and
normalization followed a three-step procedure. Firstly, a
colour bias adjustment was applied using the methylumi
R-package [30]. Then, wateRmelon [31] R-package was
used to perform between-sample normalization by
equalization of type I and type II backgrounds followed
by separated quantile normalization of methylated and
unmethylated intensities. Finally, A BMIQ [32] intra-
sample normalization procedure, included in the wateR-
melon R-package, was applied to correct the bias of type
II probe values.
Differential methylation functional profiling
The analysis of differentially methylated genes was
performed using limma [33] R-package. Data were fitted
to a linear model, and differential methylated genes were
identified by using the empirical Bayes method included
in the package. If the comparison was done between
paired samples, a moderated paired t test was applied. A
FDR-corrected p value of 0.05 was used as the threshold
to select differentially methylated genes. Functional profil-
ing of the differentially methylated genes was performed
using ClusterProfiler and the FatiScan method included in
the Babelomics [33, 34] web suite. For functional annota-
tion, the Biological Process Database from Gene Ontology
(GO) (www.geneontology.org) was used. Differentially
methylated GO biological process was represented as scat-
terplot using REVIGO online package [35].
Pyrosequencing
DNA methylation percentages of five different CpG is-
land sites included in the microarray (two in CD14,
three in HLA-DOA) were analysed and quantified by py-
rosequencing. Bisulfite-converted DNA was previously
amplified by PCR using Hot-Start GoTaq polymerase
(Promega, Madison, WI) under the following conditions:
1 ul of DNA, 4 ul of 5X polymerase buffer, 0.2 mM
dNTPs, 0.6 mM MgCl2, 0.3 μM of either biotin-labelled
forward or reverse primers and 0.05 U/μl Hot-start Go
Taq Flexi polymerase (Promega). PCR protocol was per-
formed as follows: initial denaturation at 94 °C for
2 min, 35 cycles of 94 °C 10 s, 64 °C (CD14) or 60 °C
(HLA-DOA) 10 s and 72 °C 50 s and a final extension
step of 72 °C 7 min. Details of amplicon and primer se-
quences are provided in Additional file 5: Table S3. PCR
products were verified using the QIAxcel DNA
high-resolution electrophoresis system. Pyrosequencing
of methylated sites was performed using the PyroMark
Q24 (Qiagen) according to the manufacturer’s protocol.
The methylation level was assessed using the PyroMark
Q24 2.0.6 Software (Qiagen) by which the methylation
percentage (mC/mC+C) for each CpG was calculated.
The results are presented as the percentage (mean ± SD)
of the different CpG sites studied for each of the CpG
sites analysed whose sequences and relative positions are
also shown as Additional file 5: Table S3.
Quantitative PCR for assessing mRNA expression
RNAs from 20 SACs and 22 hmMSI-H, including those
from the training set, were extracted with the miRNeasy
kit (ref: 217004, Qiagen) and used for validation by qPCR.
The retrotranscriptase reaction was performed from a
total of 1 μg of DNAseI-treated RNA using the DyNAmo
cDNA synthesis Kit (ref: F470L) provided by Thermo Sci-
entific (Rockford, IL). Five microlitres of 1:5 diluted cDNA
was added to the qPCR reaction containing 12.5 μl 2X
QuantiTect SYBR Green PCR Kit (ref:204145, Qiagen)
and 300 nM of each primer in a total volume of 25 μl.
qPCR was performed on a 7500F real-time PCR system by
Applied Biosystems (Foster City, CA, USA) according to
the instruction manual and following the standard proto-
col: 50 °C 2 min, 95 °C 10 min, 40 cycles of 95 °C 15 s,
60 °C 1 min and a melt curve stage consisting of 95 °C
15 s, 60 °C min, 95 °C 30 s and 60 °C 30 s. Primers were
designed using primer3 software and sequences, and
amplicon sizes are shown in Additional file 5: Table S3.
The relative quantitation was done by the 2-ΔCt method
using β-actin as the housekeeping gene.
Immunohistochemistry
The validation subset consisted of 26 SAC and 21
hmMSI-H cases matched for gender, age and location, and
a representative area of each tumour was selected by one of
us (JGS). Whole 2.5-μm sections were stained with CD14
and HLADOA rabbit antibodies. Details on equipment,
antigen retrieval conditions (buffer, pH, temperature, time)
and incubation (temperature, time) for both antibodies are
as follows: Bechmark Ultra Ventana, (CC1, basic, 95 °C,
56 min) and (overnight, room temperature). Antibody pur-
veyor and type, code (clone) and antibody dilution were as
follows: for CD14: Cell Marque, monoclonal, 760-4523
(EPR3653), 1:5, and for HLA-DOA: Sigma Aldrich,
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polyclonal, HPA045038, 1:200. Endogenous peroxidase ac-
tivity was blocked using 0.5% H2O2 for 5 min. For
visualization of the antigen, the sections were immersed in
3,3′-diaminobenzidine (DAB) and counterstained with
Harris’ haematoxylin for 5 min. Following manufacturers´
recommendations sinusoidal histiocytes and mantle zone
from a lymph node were used as positive controls for
CD14 and HLA-DOA, respectively.
These markers were evaluated by considering a stain-
ing intensity in both the centre of the tumour and the
invasive front (1 = none or weak staining, 2 = moderate,
3 = strong) and a staining area score (A < one third, B =
between one and two thirds, C > two thirds) in a given
area. For statistical analysis, both intensity and distribu-
tion were considered.
Statistical analysis of validation data
For the analysis of quantification of methylated DNA
sequences, the data correspond to a split-plot design
with one between-subject factor defining six inde-
pendent groups of cases (SAC, CC, hmMSI-H;
tumoural and non-tumoural) and one within-subject
factor (CpG sites) defining nine repeated measures for
every case. Accordingly, we performed two ANOVA
SPF-p-q. The first compared the means of the
tumoural vs. non-tumoural groups in each of the nine
different CpG sites and the second the means of the
six different groups in these sites. For checking the
relationship between methylation percentage and bin-
ary variables, the t test for independent samples and
the Mann-Whitney’s U test were used. Statistical sig-
nificance in the immunohistochemistry study was
assessed using Pearson χ2 or Fisher’s exact test when
indicated. Descriptive statistics were computed for
real-time PCR. Statistical analysis was performed
using the SPSS (Version 22, Chicago, IL) package.
Additional files
Additional file 1: Table S1. Gene Ontology biological processes (BP)
terms differentially enriched in the comparison SAC vs. hmMSI-H; 40 ob-
tained using ClusterProfiler and 76 using FatiGo. (XLSX 25 kb)
Additional file 2: Figure S1. Terms of Gene Ontology Cellular Component
and Molecular Functions enriched in the comparison between SAC and
hmMSI-H for their methyloma profile. The scatterplot shows the terms which
are globally differentially methylated between SAC and hmMSI-H after GO
term redundancy reduction. The graph is represented in a two dimensional
space derived by applying multidimensional scaling to a matrix of the GO
terms’ semantic similarities [35]. (TIF 162 kb)
Additional file 3: Table S2. List of the 1540 differentially methylated
genes between hmMSI-H and SAC. (XLSX 149 kb)
Additional file 4: Molecular functions of the 42 most differentially
methylated genes. Source https://www.ncbi.nlm.nih.gov/gene.
(DOCX 23 kb)
Additional file 5: Table S3. Primer sequences, amplicon sizes and
location of CpGs evaluated in the study. (DOC 48 kb)
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